Spots Global Cancer Trial Database for Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia
Official Title: A Phase 1/2, Open-Label, Multi-Center Dose Escalation, Safety and Tolerability Study of AKN-028 in Patients With Acute Myelogenous Leukemia (AML)
Study ID: NCT01573247
Conditions
Interventions
Study Description
Brief Summary: This Phase 1/2 study consists of two parts. The purpose of Part 1 of the study is to examine the safety and tolerability of AKN-028 and to determine the recommended dose of AKN-028 for further evaluation in Part 2 of the study in patients with Acute Myelogenous Leukemia (AML). The purpose of Part 2 of the study is to determine safety and efficacy in patients with AML.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Hospital Brno, Brno, , Czech Republic
University Hospital Kralovske Vinohrady, Prague, , Czech Republic
MTZ Clinical Research Inc., Warsaw, , Poland
Institute of Hematology and Transfusion Medicine, Warsaw, , Poland
Sahlgrenska University Hospital, Gothenburg, , Sweden
Orebro University Hospital, Orebro, , Sweden
Uppsala University Hospital, Uppsala, , Sweden
St.Bartholomew's Hospital, West Smithfield, , United Kingdom
Contact Details
Name: Martin Höglund, MD, PhD
Affiliation: Dept of Hematology, Uppsala University Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
